HDV IgM ELISA Kit (DEIA1896)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
plasma, serum
Species Reactivity
Human
Intended Use
Enzyme Linked Immuno Sorbent Assay (ELISA) for the determination of IgM class antibodies to Hepatitis Delta Virus or HDV in human plasma and sera with the "capture" system. The kit is intended for the classification of the viral infective agent and the follow-up of HDV infected patients.
Contents of Kit
1. Microplate: 12 strips of 8 break-apart wells
2. Negative Control: 1 x 2.0 mL/vial.
3. Positive Control: 1 x 2.0 mL/vial.
4. Calibrator, 1 vial.
5. Wash buffer concentrate, 1 x 60 mL/bottle.
6. Enzyme Conjugate 20X, 1 x 0.8 mL/vial
7. HDV Antigen, 1 x 6 vials
8. HDV Antigen Diluent
9. Specimen Diluent, 2 x 60.0 mL/vial
10. Chromogen/Substrate, 1 x 16 mL/vial.
11. Sulphuric Acid, 1 x 15 mL/vial. Contains 0.3 M H2SO4 solution.
12. Plate sealing foils
13. Package insert: 1
Storage
For more detailed information, please download the following document on our website.
Sensitivity
> 98 %

Citations


Have you cited DEIA1896 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Delta Hepatitis Positivity in Hepatitis B Virus Infected Patients; Coinfection or Superinfection?

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI

Authors: Aydemir, Ozlem; Terzi, Huseyin Agah; Karakece, Engin; Koroglu, Mehmet; Altindis, Mustafa

Introduction: Hepatitis D virus, a defective virus that requires active hepatitis B virus replication, can only infect people with active HBV infection. The clinical picture of patients super-infected with HDV proceeds rapidly and progressively. Eventually, cirrhosis, liver failure and hepatocellular carcinoma may occur. In this study, it was aimed to investigate both HDV seroprevalence and coinfection/superinfection frequency in HDV infected patients in our region. Materials and Methods: A total of 740 patients (2015-2018) with HBsAg positivity were included in the study. The results of HDV Ab, HDV Ag, anti-HBe, HBe Ag, anti-HBc IgM and IgG, ALT and AST were examined in these patients. Results: 60% of the patients were males and 40% were females. HDV Ab positivity was detected in 10 (1.36%) of the 740 HBsAg positive patients. HDV Ag positivity was detected in four patients, whereas HDV Ag and Ab positivity was detected in only one patient. ALT and AST elevations were found in 3 of the patients (30%) with Delta antibody positivity. Anti-HBc IgG was positive in all patients with Delta ab positivity and there was no antiHBclgM positivity. Conclusion: In this study, HDV prevalence detected in our region was 1.36%, which is below the general average of Turkey. There is superinfection in the whole of what we identify as HDV Ab positive. In order to combat HDV infection, in addition to immunizing those who have not had Hepatitis B infection and the nonimmune community, transmission routes of HBV must be enlightened and the epidemiology of the disease must be well known. Screening of HBV-infected individuals for HDV will help identify infected persons and contribute to protection, control and treatment programs.

Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Authors: Jang, Tyng-Yuan; Wei, Yu-Ju; Hsu, Cheng-Ting; Hsu, Po-Yao; Liu, Ta-Wei; Lin, Yi-Hung; Liang, Po-Cheng; Hsieh, Meng-Hsuan; Ko, Yu-Min; Tsai, Yi-Shan; Chen, Kuan-Yu; Lin, Ching-Chih; Tsai, Pei-Chien; Wang, Shu-Chi; Huang, Ching-, I; Yeh, Ming-Lun; Lin, Zu-Yau; Chen, Shinn-Cherng; Chuang, Wan-Long; Huang, Jee-Fu; Dai, Chia-Yen; Huang, Chung-Feng; Yu, Ming-Lung

Background and Aim The serial serologic changes of hepatitis D virus (HDV) infection among chronic hepatitis B virus (HBV) infected patients who received oral nucleotide/nucleoside analogues are elusive. Methods Serum anti-HDV and HDV RNA among chronic hepatitis B (CHB) patients were tested at the time of initiating anti-HBV therapy and subsequently during the follow-up period. Results The seropositive rate of anti-HDV and HDV RNA among 2850 CHB patients, was 2.7% and 0.9%, respectively. Factors associated with anti-HDV seropositivity were platelet counts (odds ratio [OR]/95% confidence intervals [CI]: 0.995/0.992-0.999; P = 0.006), HBV DNA levels (OR/CI: 0.81/0.70-0.94; P = 0.005), and hepatitis B e-antigen (HBeAg) seropositivity (OR/CI: 0.22/0.05-0.95; P = 0.04). The only factor associated with HDV RNA positivity among anti-HDV seropositive patients was age (OR/CI: 0.95/0.90-1.00; P = 0.03). The spontaneous clearance rate of serum anti-HDV antibody was 3.0 per 100 person-years with a median follow-up period of 3.5 years (range 2-12 years), whereas the seroclearance rate of HDV RNA was 4.3 per 100 person-years among anti-HDV seropositive patients after a median follow-up period of 6.0 years (range 2-11 years). A baseline anti-HDV titer < 0.5 cut-off index was the only factor predictive of anti-HDV seroclearance (hazard ratio [HR]/CI: 30.11/3.73-242.85; P = 0.001). Conclusions HDV infection was not common among patients treated for HBV in Taiwan. Seroclearance of anti-HDV and HDV RNA did occur over time, albeit the chance is rare.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket